Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

NCT01226056 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

SUSPENDED

Status

45

Enrollment

OTHER

Sponsor class

Stopped toxicity (protocol amendment under approval)

Conditions

Advanced Solid Tumors

Interventions

DRUG: RAD001 in combination with sorafenib

Sponsor

Southern Europe New Drug Organization

Collaborators

[object Object]
[object Object]